CARTITUDE-1 Safety Overview

EP: 1.Treatment Approaches in Multiple Myeloma

EP: 2.FDA Approvals for Multiple Myeloma

EP: 3.CARTITUDE-1 Baseline Demographics

EP: 4.An Overview of CARTITUDE-1

EP: 5.CARTITUDE-1 Patients

EP: 6.CARTITUDE-1 Efficacy Findings

Now Viewing

EP: 7.CARTITUDE-1 Safety Overview

EP: 8.CARTITUDE-1 Primary Findings Discussion

Safety data indicate that ciltacabtagene autoleucel is generally well tolerated, with hematologic toxicities such as neutropenia and anemia being the most common adverse effects. These are expected with lymphodepleting chemotherapy and are manageable.

Class-specific toxicities such as CRS and immune effector cell–associated neurotoxicity syndrome occurred but were mostly grade 1 or 2. Both conditions were manageable with existing supportive care measures, including tocilizumab and steroids.

Rare but notable late-onset neurotoxicities resembling parkinsonism were linked to high chimeric antigen receptor T-cell expansion and tumor burden. Enhanced disease control and improved patient selection have helped mitigate these risks in recent cohorts.